Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

1.

PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity.

Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, Painter CL, Wong A, Kraynov E, Arango ME, Mehta PP, Popoff I, Casperson GF, Los G, Bender S, Anderes K, Christensen JG, VanArsdale T.

Clin Cancer Res. 2010 Nov 1;16(21):5177-88. doi: 10.1158/1078-0432.CCR-10-1343. Epub 2010 Sep 9.

PMID:
20829331
[PubMed - indexed for MEDLINE]
Free Article
2.

Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.

Lamszus K, Brockmann MA, Eckerich C, Bohlen P, May C, Mangold U, Fillbrandt R, Westphal M.

Clin Cancer Res. 2005 Jul 1;11(13):4934-40.

PMID:
16000592
[PubMed - indexed for MEDLINE]
Free Article
3.

Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer.

Kundu N, Beaty TL, Jackson MJ, Fulton AM.

J Natl Cancer Inst. 1996 Apr 17;88(8):536-41.

PMID:
8606382
[PubMed - indexed for MEDLINE]
Free Article
4.

Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.

Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, Dinney CP.

Clin Cancer Res. 2001 Sep;7(9):2840-53.

PMID:
11555602
[PubMed - indexed for MEDLINE]
Free Article
5.

Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.

Garcia de Palazzo I, Holmes M, Gercel-Taylor C, Weiner LM.

Cancer Res. 1992 Oct 15;52(20):5713-9.

PMID:
1394194
[PubMed - indexed for MEDLINE]
Free Article
6.

[Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].

Wang YD, Hu Y, Zhang L, Huang J, Sun CY.

Zhonghua Xue Ye Xue Za Zhi. 2007 Oct;28(10):659-63. Chinese.

PMID:
18399169
[PubMed - indexed for MEDLINE]
7.

Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer.

Green SK, Karlsson MC, Ravetch JV, Kerbel RS.

Cancer Res. 2002 Dec 1;62(23):6891-900.

PMID:
12460904
[PubMed - indexed for MEDLINE]
Free Article
8.

The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines.

Coleman EJ, Brooks KJ, Smallshaw JE, Vitetta ES.

J Immunother. 2006 Sep-Oct;29(5):489-98.

PMID:
16971805
[PubMed - indexed for MEDLINE]
9.

A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.

Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I.

Cancer Res. 1993 Jan 1;53(1):94-100.

PMID:
8093231
[PubMed - indexed for MEDLINE]
Free Article
10.

The generation and anti-myeloma activity of a chimeric anti-CD54 antibody, cUV3.

Smallshaw JE, Coleman E, Spiridon C, Vitetta ES.

J Immunother. 2004 Nov-Dec;27(6):419-24.

PMID:
15534485
[PubMed - indexed for MEDLINE]
11.

Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.

Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, Jimenez X, Deevi DS, Iacolina M, Kayas A, Bassi R, Persaud K, Rohoza-Asandi A, Balderes P, Loizos N, Ludwig DL, Tonra J, Witte L, Zhu Z.

Neoplasia. 2009 Jun;11(6):594-604.

PMID:
19484148
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Tumor specificity and in vivo targeting of an antibody against exon 9 deleted E-cadherin in gastric cancer.

Lee HJ, Lee HS, Hur K, Kim WH, Yanagihara K, Becker KF, Lee KU, Yang HK.

J Cancer Res Clin Oncol. 2007 Dec;133(12):987-94. Epub 2007 Jun 19.

PMID:
17576594
[PubMed - indexed for MEDLINE]
13.

CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo.

Trikha M, Zhou Z, Nemeth JA, Chen Q, Sharp C, Emmell E, Giles-Komar J, Nakada MT.

Int J Cancer. 2004 Jun 20;110(3):326-35.

PMID:
15095296
[PubMed - indexed for MEDLINE]
14.

Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis.

Burden RE, Gormley JA, Jaquin TJ, Small DM, Quinn DJ, Hegarty SM, Ward C, Walker B, Johnston JA, Olwill SA, Scott CJ.

Clin Cancer Res. 2009 Oct 1;15(19):6042-51. doi: 10.1158/1078-0432.CCR-09-1262. Epub 2009 Sep 29.

PMID:
19789302
[PubMed - indexed for MEDLINE]
Free Article
15.

Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.

Funakoshi S, Longo DL, Murphy WJ.

J Immunother Emphasis Tumor Immunol. 1996 Mar;19(2):93-101.

PMID:
8732692
[PubMed - indexed for MEDLINE]
16.

Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.

Liao F, Doody JF, Overholser J, Finnerty B, Bassi R, Wu Y, Dejana E, Kussie P, Bohlen P, Hicklin DJ.

Cancer Res. 2002 May 1;62(9):2567-75.

PMID:
11980651
[PubMed - indexed for MEDLINE]
Free Article
17.

P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.

Joshi KS, Rathos MJ, Mahajan P, Wagh V, Shenoy S, Bhatia D, Chile S, Sivakumar M, Maier A, Fiebig HH, Sharma S.

Mol Cancer Ther. 2007 Mar;6(3):926-34.

PMID:
17363487
[PubMed - indexed for MEDLINE]
Free Article
18.

A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis.

Yi M, Ruoslahti E.

Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):620-4.

PMID:
11209058
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.

Maruyama-Takahashi K, Shimada N, Imada T, Maekawa-Tokuda Y, Ishii T, Ouchi J, Kusaka H, Miyaji H, Akinaga S, Tanaka A, Shitara K.

Prostate. 2008 May 1;68(6):640-50. doi: 10.1002/pros.20728.

PMID:
18213631
[PubMed - indexed for MEDLINE]
20.

Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo.

Chen C, Li G, Liao W, Wu J, Liu L, Ma D, Zhou J, Elbekai RH, Edin ML, Zeldin DC, Wang DW.

J Pharmacol Exp Ther. 2009 Jun;329(3):908-18. doi: 10.1124/jpet.109.152017. Epub 2009 Mar 16.

PMID:
19289568
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk